EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Endologix Inc. -
ELGX
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of
shareholders of Endologix Inc. (NASDAQ:ELGX) resulting from allegations that Endologix may have issued materially misleading
business information to the investing public.
Nellix is Endologix’s endovascular aneurysm sealing system for infrarenal abdominal aortic aneurysms. On August 2, 2016, CEO
John McDermott indicated that Endologix would seek approval of the original version of the Nellix system that was used in the
Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study, given that Endologix had the needed
clinical data. On November 16, 2016, Endologix announced that the FDA has requested two-year follow-up data on patients enrolled in
the EVAS-FORWARD-IDE study to assess Nellix. On this news, shares of Endologix Inc. fell $2.02 per share or over 20% to close at
$7.82 per share on November 16, 2016, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Endologix investors. If you purchased shares of
Endologix, please visit the firm’s website at http://www.rosenlegal.com/cases-999.html for more information. You may also contact Phillip Kim or Kevin Chan of
Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder
derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: 212-686-1060
Toll Free: 866-767-3653
Fax: 212-202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161116006709/en/